Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
4 days ago
Daily intake of cow’s milk formula in early life helps prevent the development of cow’s milk allergy later on without competing with breastfeeding, a recent study has found.

Epicutaneous immunotherapy a durable treatment option against peanut allergies

12 Oct 2020
A wearable patch has been developed to treat children and young adults with peanut allergy

Continued daily treatment with epicutaneous immunotherapy (EPIT) elicits a stable response in children with peanut allergies, a recent study has found.

The PEOPLE* study is an ongoing 5-year extension of the PEPITES** trial and seeks to determine the efficacy and safety of continued EPIT in kids with peanut allergies. The current report presented the 2-year interim findings of a month-36 double-blind, placebo-controlled food challenge.

A total of 141 children completed all treatment as per the study protocol and were eligible for efficacy assessment. Over half (51.8 percent; n=73) achieved an eliciting dose (ED) of ≥1,000 mg at the 36-month check-in, as compared to only 40.4 percent (n=57) at month 12. After 3 years of treatment, 75.9 percent of participants saw an increase in ED from baseline.

Notably, 13.5 percent (n=19) of the participants became able to tolerate the full double-blind placebo-controlled food challenge dose of 5,444 mg, and researchers reported an increase in the median reactive dose, jumping from 144 mg at baseline to 944 mg at month 36.

Eighteen patients were included in the sustained unresponsiveness evaluation, where 77.8 percent (n=14) had maintained an ED ≥1,000 mg at 38 months despite being off treatment.

In terms of safety, researchers reported that only 1 percent of the patients withdrew from the study due to treatment-related adverse events. By years 2 and 3, there were no documented treatment-related uses of epinephrine. Overall compliance was high, at 96.9 percent.

“Data presented here suggest that EPIT may represent a persistent and durable treatment option, on a background of being well tolerated. Moreover, EPIT has minimal impact or restrictions on daily activities and lifestyle and is easy to use, resulting in high compliance rates,” researchers said.

*PEPITES Open-Label Extension

**Peanut EPIT Efficacy and Safety

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
4 days ago
Daily intake of cow’s milk formula in early life helps prevent the development of cow’s milk allergy later on without competing with breastfeeding, a recent study has found.